Drugs that remove or quiet senescent cells could reduce inflammatory aging signals, but benefits depend heavily on context.
Evidence maturityEarly human
Page status
- Needs larger randomized human studies
- Needs tissue-specific benefit-risk framing
Key takeaways
- Senescent cells can be harmful, protective, or useful depending on timing and tissue.
- Intermittent dosing is attractive because the target accumulates over time.
- Frailty, fibrosis, metabolic disease, and immune aging remain major areas to watch.
Mechanism
Senolytics try to selectively kill senescent cells. Senomorphics try to reduce the inflammatory secretions those cells produce without necessarily removing them.
The central design problem is selectivity. A therapy that broadly damages stressed but useful cells can undermine repair, wound healing, or immune function.
Practical interpretation
Aging biology rarely maps to a single villain. Senescence is part of cancer suppression and tissue repair, so timing matters as much as the molecular target.
The best evidence will come from endpoints tied to function: mobility, organ performance, fibrosis, immune response, and recovery after stress.
Watchlist
- Intermittent protocols
- Combination therapies
- Frailty endpoints
- Inflammatory biomarkers
References
- Human senolytic pilot. Hickson et al., EBioMedicine, 2019. Preliminary human dasatinib plus quercetin study in diabetic kidney disease.
- Senolytic clinical follow-up. Senolytic combination clinical literature, 2024. Use for inflammation, tissue specificity, and clinical endpoint caution.
What links here
- Biohacking Risk LedgerSelf-experimentation should be judged by reversibility, measurement quality, downside planning, and evidence strength.
- Epigenetic ClocksDNA methylation clocks estimate biological age and may become trial tools, but they are not a substitute for health outcomes.
- Longevity Pharma PipelineAging-targeted pharma is moving from supplement claims toward indication-led trials, combination logic, and prevention endpoints.